Your browser doesn't support javascript.
loading
A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents.
Carpenter, Chelsea; Sidney, John; Kolla, Ravi; Nayak, Kaustuv; Tomiyama, Helena; Tomiyama, Claudia; Padilla, Oscar A; Rozot, Virginie; Ahamed, Syed F; Ponte, Carlos; Rolla, Valeria; Antas, Paulo R; Chandele, Anmol; Kenneth, John; Laxmi, Seetha; Makgotlho, Edward; Vanini, Valentina; Ippolito, Giuseppe; Kazanova, Alexandra S; Panteleev, Alexander V; Hanekom, Willem; Mayanja-Kizza, Harriet; Lewinsohn, David; Saito, Mayuko; McElrath, M Juliana; Boom, W Henry; Goletti, Delia; Gilman, Robert; Lyadova, Irina V; Scriba, Thomas J; Kallas, Esper G; Murali-Krishna, Kaja; Sette, Alessandro; Lindestam Arlehamn, Cecilia S.
Afiliación
  • Carpenter C; La Jolla Institute for Allergy and Immunology, Department of Vaccine Discovery, 9420 Athena Circle, La Jolla, 92037, USA.
  • Sidney J; La Jolla Institute for Allergy and Immunology, Department of Vaccine Discovery, 9420 Athena Circle, La Jolla, 92037, USA.
  • Kolla R; La Jolla Institute for Allergy and Immunology, Department of Vaccine Discovery, 9420 Athena Circle, La Jolla, 92037, USA.
  • Nayak K; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India.
  • Tomiyama H; Division of Clinical Immunology and Allergy, University of São Paulo Medical School, São Paulo, Brazil.
  • Tomiyama C; Division of Clinical Immunology and Allergy, University of São Paulo Medical School, São Paulo, Brazil.
  • Padilla OA; Division of Clinical Immunology and Allergy, University of São Paulo Medical School, São Paulo, Brazil.
  • Rozot V; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Department of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Ahamed SF; Division of Infectious Diseases, St. John's Research Institute, St. John's National Academy of Sciences, Sarjapur Road, Koramangala 2 Block, Bangaluru, Karnataka, 560034, India.
  • Ponte C; Clinical Immunology Laboratory, Oswaldo Cruz Institute-Fiocruz, Rio de Janeiro, Brazil.
  • Rolla V; Clinical Immunology Laboratory, Oswaldo Cruz Institute-Fiocruz, Rio de Janeiro, Brazil.
  • Antas PR; Clinical Immunology Laboratory, Oswaldo Cruz Institute-Fiocruz, Rio de Janeiro, Brazil.
  • Chandele A; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India.
  • Kenneth J; Division of Infectious Diseases, St. John's Research Institute, St. John's National Academy of Sciences, Sarjapur Road, Koramangala 2 Block, Bangaluru, Karnataka, 560034, India.
  • Laxmi S; Department of Transfusion Medicine and Immunohematology, St. John's Medical College Hospital, St. John's National Academy of Health Sciences, Bangaluru, 560034, India.
  • Makgotlho E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Department of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Vanini V; Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases, Rome, Italy.
  • Ippolito G; Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases, Rome, Italy.
  • Kazanova AS; Department of Immunology, Federal State Budgetary Scientific Institution "Central Tuberculosis Research Institute", Moscow, Russia.
  • Panteleev AV; Department of Immunology, Federal State Budgetary Scientific Institution "Central Tuberculosis Research Institute", Moscow, Russia.
  • Hanekom W; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Department of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Mayanja-Kizza H; Department of Medicine, College of Health Sciences, Faculty of Medicine, Makerere University, Kampala, Uganda.
  • Lewinsohn D; Oregon Health and Science University, Portland, 97239, USA.
  • Saito M; Johns Hopkins University, Bloomberg School of Public Health, Baltimore, 21205, USA; Universidad Peruana Caytano Hereida, Lima, Peru; Department of Virology, Tohoku University, Sendai, Japan.
  • McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, 98109, USA.
  • Boom WH; Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, 44106, USA.
  • Goletti D; Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases, Rome, Italy.
  • Gilman R; Johns Hopkins University, Bloomberg School of Public Health, Baltimore, 21205, USA; Universidad Peruana Caytano Hereida, Lima, Peru.
  • Lyadova IV; Department of Immunology, Federal State Budgetary Scientific Institution "Central Tuberculosis Research Institute", Moscow, Russia.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Department of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
  • Kallas EG; Division of Clinical Immunology and Allergy, University of São Paulo Medical School, São Paulo, Brazil.
  • Murali-Krishna K; ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India; Emory Vaccine Center, 1501 Clifton Road, Atlanta, GA, 30329, USA; Department of Pediatrics, Emory University, 1760 Haygood Drive, Atlanta, GA, 30322, USA.
  • Sette A; La Jolla Institute for Allergy and Immunology, Department of Vaccine Discovery, 9420 Athena Circle, La Jolla, 92037, USA.
  • Lindestam Arlehamn CS; La Jolla Institute for Allergy and Immunology, Department of Vaccine Discovery, 9420 Athena Circle, La Jolla, 92037, USA. Electronic address: cecilia@lji.org.
Tuberculosis (Edinb) ; 95(6): 713-721, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26277695
ABSTRACT
We compared T cell recognition of 59 prevalently recognized Mycobacterium tuberculosis (MTB) antigens in individuals latently infected with MTB (LTBI), and uninfected individuals with previous BCG vaccination, from nine locations and populations with different HLA distribution, MTB exposure rates, and standards of TB care. This comparison revealed similar response magnitudes in diverse LTBI and BCG-vaccinated cohorts and significant correlation between responses in LTBIs from the USA and other locations. Many antigens were uniformly recognized, suggesting suitability for inclusion in vaccines targeting diverse populations. Several antigens were similarly immunodominant in LTBI and BCG cohorts, suggesting applicability for vaccines aimed at boosting BCG responses. The panel of MTB antigens will be valuable for characterizing MTB-specific CD4 T cell responses irrespective of ethnicity, infecting MTB strains and BCG vaccination status. Our results illustrate how a comparative analysis can provide insight into the relative immunogenicity of existing and novel vaccine candidates in LTBIs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 3_ND Problema de salud: 1_doencas_transmissiveis / 2_enfermedades_transmissibles / 3_neglected_diseases / 3_tuberculosis / 3_zoonosis Asunto principal: Linfocitos T CD4-Positivos / Tuberculosis Latente / Mycobacterium tuberculosis / Antígenos Bacterianos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Africa / America do norte / America do sul / Asia / Brasil / Europa Idioma: En Revista: Tuberculosis (Edinb) Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 3_ND Problema de salud: 1_doencas_transmissiveis / 2_enfermedades_transmissibles / 3_neglected_diseases / 3_tuberculosis / 3_zoonosis Asunto principal: Linfocitos T CD4-Positivos / Tuberculosis Latente / Mycobacterium tuberculosis / Antígenos Bacterianos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Africa / America do norte / America do sul / Asia / Brasil / Europa Idioma: En Revista: Tuberculosis (Edinb) Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos